Incyte (INCY) Other Accumulated Expenses (2017 - 2022)
Incyte's (INCY) quarterly Other Accumulated Expenses came in at $209.5 million in Q2 2022, up 64.68% YoY from $127.2 million in Q2 2021, and up 21.83% on a QoQ basis from $172.0 million in Q1 2022.
Incyte (INCY) Other Accumulated Expenses (2017 - 2022) Analysis & Trends
Incyte (INCY) has 6 years of Other Accumulated Expenses data on file, last reported at $209.5 million in Q2 2022.
- Quarterly Other Accumulated Expenses rose 64.68% year-over-year to $209.5 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $209.5 million (up 64.68% YoY) and the FY2021 annual result came in at $168.4 million, up 58.86% from the prior year.
- Other Accumulated Expenses climbed to $209.5 million in Q2 2022, from $172.0 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $209.5 million in Q2 2022 to a low of $34.6 million in Q4 2018.
- A 5-year average of $105.3 million and a median of $99.1 million in 2020 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2019 — Other Accumulated Expenses soared 111.82% — and 2020, when it jumped 44.78%.
- Tracing INCY's Other Accumulated Expenses over 5 years: stood at $34.6 million in 2018, then soared by 111.82% to $73.2 million in 2019, then jumped by 44.78% to $106.0 million in 2020, then surged by 58.86% to $168.4 million in 2021, then grew by 24.4% to $209.5 million in 2022.
- The last three Other Accumulated Expenses figures came in at $209.5 million (Q2 2022), $172.0 million (Q1 2022), and $168.4 million (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 209.50 Mn |
| Mar 31, 2022 | 171.96 Mn |
| Dec 31, 2021 | 168.41 Mn |
| Sep 30, 2021 | 142.45 Mn |
| Jun 30, 2021 | 127.22 Mn |
| Mar 31, 2021 | 110.10 Mn |
| Dec 31, 2020 | 106.01 Mn |
| Sep 30, 2020 | 92.15 Mn |
| Jun 30, 2020 | 77.80 Mn |
| Mar 31, 2020 | 73.05 Mn |
| Dec 31, 2019 | 73.22 Mn |
| Jun 30, 2019 | 47.40 Mn |
| Mar 31, 2019 | 39.91 Mn |
| Dec 31, 2018 | 34.57 Mn |
| Dec 31, 2017 | 22.81 Mn |